HER2 as a targetable biomarker in gastrointestinal oncology

touchEXPERT FOCUS for touchONCOLOGY Listen to a series of short interviews with three leading experts as they discuss the use of HER2 as a targetable biomarker in gastrointestinal oncology. The faculty cover the clinical significance of HER2 alterations, best practices for biomarker testing, key clinical trial data on efficacy and safety, and the role of HER2-targeted therapies in both common and rare GI cancers. They also address retesting at progression, management of adverse events, and emerging treatment approaches. The experts Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, New York, NY, USA Prof. Eric Van Cutsem, University of Leuven, Leuven, Belgium Prof. Florian Lordick, University of Leipzig, Leipzig, Germany This touchPODCAST is for HCPs outside of the UK This activity is funded by an independent medical education grant from AstraZeneca.  This activity is jointly provided by USF Health and touchIME.  touchIME is an EBAC® accredited provider.  For further information visit our website:  www.touchONCOLOGY.com